|
|
Scientific Advisory Board
Lewis Cantley, Ph.D.
Lynda Chin, M.D.
Steven C. Clark, Ph.D.
Ronald A. DePinho, M.D.
Douglas Hanahan, Ph.D.
H. Robert Horvitz, Ph.D.
Tyler Jacks, Ph.D.
Richard D. Klausner, M.D.
Raju Kucherlapati, Ph.D.
David M. Livingston, M.D.
Charles L. Sawyers, M.D.
Edward M. Scolnick, M.D. Lewis Cantley, Ph.D.
Dr. Cantley is a Professor of Systems Biology at Harvard Medical School and Chief of the Division of Signal Transduction at Beth Israel Deaconess Medical Center. Dr. Cantley graduated suma cum laude with a B.S. in Chemistry from W.V. Wesleyan College in 1971 and obtained a Ph.D. in Biophysical Chemistry from Cornell University in 1975. He did postdoctoral research at Harvard from 1975 until 1978 and joined the Department of Biochemistry and Molecular Biology as an Assistant Professor in 1978. Dr. Cantley's early work focused on the structure and mechanism of enzymes that transport small molecules across cell membranes and he pioneered the application of fluorescence resonance energy transfer (FRET) for studying such processes. His early studies also led to the discovery that vanadate can act as a high affinity transition state analog inhibitor of enzymes with phosphorylated intermediates. In the mid-1980s, Dr. Cantley focused his research on biochemical mechanisms of cellular responses to hormones and growth factors. This work led to the discovery of the phosphoinositide 3-kinase (PI3K) signaling pathway. His subsequent research as a Professor at Tufts University School of Medicine (1985-1992) and at Harvard Medical School (1992-present) has focused on characterizing the mechanism by which PI3K is activated by growth factors and oncogenes and elucidating pathways downstream of PI3K, including the AKT/PKB signaling pathway. In the course of this work, Dr. Cantley's laboratory developed an oriented peptide library approach that has revealed the structural basis for regulated interaction of signaling proteins. This technique has also led to a bioinformatics approach for predicting signaling pathways on the basis of gene sequences. Currently, Dr. Cantley is exploring the role of the PI3K pathway in cancer and diabetes by developing mouse models in which genes for enzymes in this pathway are altered. Dr. Cantley was elected to the American Academy of Arts and Sciences in 1999 and to the National Academy of Sciences in 2001. Among his other awards are the ASBMB Avanti Award for Lipid Research (1998), the Heinrich Weiland Preis for Lipid Research (2000), the Caledonian Prize from the Royal Society of Edinburgh (2002) and the AACR Pezcoller Award for Cancer Research (2005). He is a member of the Editorial Board at Cell and is an Associate Editor of the Journal of Cell Biology. Dr. Cantley has authored more than 250 scientific publications. » back to top Lynda Chin, M.D.
Dr. Chin is a co-founder of AVEO and an Associate Professor of Dermatology at the Harvard Medical School and is a board-certified dermatologist. She received her M.D. from the Albert Einstein College of Medicine and conducted her medical training at Columbia Presbyterian Medical Center and the Albert Einstein College of Medicine, where she was Chief Resident of Dermatology. She is now a member of the Department of Adult Oncology at the Dana-Farber Cancer Institute of Harvard Medical School and chairs the Skin Organ Site Committee of the Mouse Models of Human Cancer Consortium (MMHCC) of the National Cancer Institute. Dr. Chin is a leader in the field of melanoma genetics and has pioneered the construction and use of mouse models of melanoma. She is a recognized expert in the use of genomics to identify cancer-relevant genes and currently directs a cancer genomics facility for the Dana-Farber Cancer Institute. Dr. Chin pioneered the concept of tumor maintenance and the use of second-site suppression genetics in mammalian systems. She is the recipient of numerous scientific awards including the V Foundation Scholar Award, the BASF Research Award, the Culpeper Award, and the Rising Star's Award. In 2000, Dr. Chin also received the Stone Wilson Award for Cancer Research - an award that recognizes the most accomplished junior investigator conducting cancer research worldwide. » back to top Steven C. Clark, Ph.D. (Chair)Until December 2007, Dr. Clark was the Chief Scientific Officer of the Company and was instrumental in recruiting and building the scientific organization. Going forward, he will chair AVEO's Scientific Advisory Board.
Dr. Clark has 25 years of Drug Discovery experience, 21 of those years were spent with Genetics Institute and Wyeth Research, bringing together unique expertise in both protein and small-molecule therapeutics. He was a founding scientist at Genetics Institute in 1981 where he established the Hematopoiesis Program and pioneered the use of functional expression cloning for the isolation of genes for cytokines, growth factors, and their receptors. Among the cytokines cloned in his laboratory included GM-CSF, IL-3, IL-9, IL-11 and IL-12. From 1989 until 1997, he was the Vice President of Discovery Research for Genetics Institute. Through a collaboration established with Affymetrix, Discovery scientists at Genetics Institute pioneered the use of oligonucleotide arrays for transcriptional profiling. In 1997, with the merger of Wyeth and Genetics Institute, he became the Sr. Vice President of the combined discovery organizations with responsibility for 1400 scientists working in six different therapeutic areas. During his four years as the Head of Discovery at Wyeth, his organization delivered many clinical candidates to the R&D pipeline, including both proteins and small molecules. Dr. Clark did his graduate work in molecular biology at Harvard University with Dr. Richard Losick and postdoctoral work with Dr. Paul Berg at the Stanford University School of Medicine.
Ronald A. DePinho, M.D.
Dr. DePinho is a co-founder of AVEO and holds the coveted American Cancer Society Research Professorship and is Professor of Medicine and Genetics at the Harvard Medical School. He is the director of the Center for Applied Cancer Science at the Dana-Farber Cancer Institute. His research program has made major discoveries of fundamental importance to cancer medicine, aging and degenerative disorders. He has been a leader in the field of molecular genetics and in the development of mouse models of human cancer. His independent scientific career began at the Albert Einstein College of Medicine where he was the Senior Scholar in Cancer Research and launched the first mouse genome engineering program to model and study the genetic basis of cancer. He is now a member of the Department of Medical Oncology at the Dana Farber Cancer Institute and Department of Medicine and Genetics at the Harvard Medical School. Dr. DePinho is a former member the Board of Directors of the American Association for Cancer Research, chairs advisory boards for the NCI Mouse Models of Human Cancer Consortium and the NIH Human Cancer Genome Altas Project, and serves on numerous advisory boards for the public and private sectors. Dr. DePinho studied Biology at Fordham University where he graduated Class Salutatorian and received his M.D. degree with distinction in Microbiology and Immunology from the Albert Einstein College of Medicine. His honors and awards include the March of Dimes Basil O'Connor Award, James S. McDonnell Scholar Award, the Cancer Research Institute Scholar Award, the Melini Award for Biomedical Excellence, the Irma T. Hirshcl Award, Kirsch Foundation Investigator Award, and the Richard and Claire Morse Scholar Award. He is the 2002 recipient of the American Society for Clinical Investigation Award and the 2003 AACR Clowes Award. He is a member of the National Academy of Science Institute of Medicine. » back to top Douglas Hanahan, Ph.D.
Douglas Hanahan, PhD, is an American Cancer Society Professor in the Department of Biochemistry & Biophysics at the University of California, San Francisco, where he is leader of the Mouse Models of Cancer Program in the Comprehensive Cancer Center, and a member of the Diabetes Center. He received a B.S. in Physics from MIT, and a Ph.D. in Biophysics from Harvard, where he was a Harvard Junior Fellow. He worked at Cold Spring Harbor Laboratory first as a graduate student and then as a faculty member. In the mid-1980's Hanahan produced some of the first transgenic 'oncomice', genetically engineered to develop organ specific cancers, and he has used mouse models of cancer both to investigate the multistage pathways that govern tumor formation and progression, and to explore the benefits of targeted therapies (in particular anti-angiogenic strategies) aimed at different stages of disease progression; he discovered, in collaboration with Judah Folkman, the 'angiogenic switch', which is activated to produce new blood vessels in early stage neoplastic lesions preceding overt tumors. Dr. Hanahan also developed high efficiency plasmid transformation methods and E. coli strains (e.g. DH5) that have facilitated DNA cloning procedures; his work on E. coli transformation (the production of 'competent cells') substantively enabled the development of a research products industry that currently supports molecular genetics research in the life sciences worldwide. Dr. Hanahan has over 150 publications, including a number of influential perspectives, notably one coauthored with Judah Folkman on 'the angiogenic switch' that is a defining event for most cancers, and another with Bob Weinberg on 'the hallmarks of cancer', which presented an organizing principle for interrelating the genetic and phenotypic complexity of tumors in diverse organs as different means to the same end, in the form of a common set of acquired capabilities necessary for their manifestation. » back to top H. Robert Horvitz, Ph.D.
Dr. H. Robert Horvitz received the Nobel Prize in Physiology or Medicine in 2002. He is the David H. Koch Professor of Biology at the Massachusetts Institute of Technology; an Investigator of the Howard Hughes Medical Institute; Neurobiologist (Neurology) and Geneticist (Medicine) at the Massachusetts General Hospital; and a Member of the McGovern Institute for Brain Research and the MIT Center for Cancer Research. Dr. Horvitz received S.B. degrees in Mathematics and in Economics from the Massachusetts Institute of Technology in 1968. He performed his graduate studies at Harvard University in the laboratories of Drs. James Watson and Walter Gilbert and received his Ph.D. in 1974 for his biochemical and genetic analyses of modifications of the E. coli RNA polymerase induced by bacteriophage T4. Dr. Horvitz then joined Dr. Sydney Brenner at the Medical Research Council Laboratory of Molecular Biology in Cambridge, England, and there began studies of the development and behavior of the nematode Caenorhabditis elegans. Dr. Horvitz became an Assistant Professor in the Department of Biology at the Massachusetts Institute of Technology in 1978 and became Associate Professor in 1981 and Professor in 1986. He was named Whitehead Professor of Biology in 1999 and David H. Koch Professor of Biology in 2000. Dr. Horvitz has served on many editorial boards, visiting committees and advisory committees, including as a member of the Advisory Council of the National Human Genome Research Institute (N.I.H.) and of the Chair's Advisory Committee of the Joint Steering Committee for Public Policy. He was Co-chair of the Working Group on Preclinical Models for Cancer of the National Cancer Institute. Dr. Horvitz was President of the Genetics Society of America in 1995. Dr. Horvitz has received numerous awards for his accomplishments, including the Charles A. Dana Award for Pioneering Achievements in Health (1995); the Ciba-Drew Award for Biomedical Science (1996); the General Motors Cancer Research Foundation Alfred P. Sloan, Jr. Prize (1998); the Gairdner Foundation International Award (Toronto, Canada, 1999); the March of Dimes Prize in Developmental Biology (2000); the Genetics Society of America Medal (2001); the Bristol-Myers Squibb Award for Distinguished Achievement in Neuroscience (2001); the Wiley Prize in the Biomedical Sciences (2002); the Peter Gruber Foundation Genetics Prize (2002); the American Cancer Society Medal of Honor (2002); and the Alfred G. Knudson Award of the National Cancer Institute (2005). Dr. Horvitz was elected to the U.S. National Academy of Sciences in 1991, to the U.S. Institute of Medicine in 2003, to the American Philosophical Society in 2004, a Fellow of the American Academy of Arts and Sciences in 1994 and a Fellow of the American Academy of Microbiology in 1997. Dr. Horvitz received an Honorary M.D. from the University of Rome (2004) and an Honorary D.Sc. from Cambridge University (2004). He has been a consultant to a number of pharmaceutical companies and was cofounder of the biotechnology companies NemaPharm, Inc. and Idun Pharmaceuticals. » back to top Tyler Jacks, Ph.D.
Dr. Jacks is the Director of the Center for Cancer Research at the Massachusetts Institute of Technology. He is also Professor of Biology at MIT. Dr. Jacks received his B.A. from Harvard College, where he graduated magna cum laude with Highest Honors in Biology in 1983. His graduate thesis was performed with Harold Varmus at the University of California, San Francisco, and he was a postdoctoral fellow with Robert Weinberg at the Whitehead Institute at MIT. Dr. Jacks joined the faculty at MIT in 1992. He has pioneered the use of gene-targeting technology in the mouse to study cancer-associated genes and to construct mouse models of many human cancer types. His laboratory has made seminal contributions to the construction of novel mouse models of human cancer and to the understanding of the effects of mutations of several tumor suppressor genes on tumor development, normal development and other cellular processes, including apoptosis, cell cycle control, intracellular signaling and cell migration. Tumor suppressor genes currently under study in his laboratory include the Rb family, the p53 family, Nf1 and Nf2. Dr. Jacks served on the Board of Scientific Advisors of the National Cancer Institute (NCI) and the Board of Directors of the American Association of Cancer Research (AACR); he is also co-Chair of the Research Advisory Board of the National Neurofibromatosis Foundation; and also co-Chair of the steering committee of the NCI-sponsored Mouse Models of Cancer Consortium. Dr. Jacks was a Merck Fellow of the Helen Hay Whitney Foundation, a Markey Scholar and a Searle Scholar. In recognition to his contribution to our understanding of cancer genetics, he has received the AACR Cornelius P. Rhoads Memorial Award and the Amgen Award from the American Society of Biochemistry and Molecular Biology. He was the 2002 recipient of the Chestnut Hill Award for Excellence in Medical Research. Dr. Jacks received the 2005 Paul Marks Prize for Cancer Research. » back to top Richard D. Klausner, M.D.
Dr. Klausner is Chairman and Managing Director, The Column Group, former Executive Director, Global Health Program, Bill & Melinda Gates Foundation, and former Head of the National Cancer Institute (NCI), received a B.S. in Molecular Biophysics and Biochemistry from Yale University and an M.D. from Duke University. Prior to joining the Foundation, Dr. Klausner was Special Advisor to the National Academy and Liaison to the President on Anti-Terrorism as well as former Director of the NCI. Dr. Klausner trained in internal medicine at Massachusetts General Hospital and was a fellow in internal medicine at Duke Medical Center in 1976-1977. From 1979-1981, following additional training in internal medicine at Massachusetts General Hospital, Dr. Klausner began his research career at the National Institutes of Health in NCI's Laboratory of Mathematical Biology. He worked at NIADDK from 1981-1984, when he became chief of the Cell Biology and Metabolism Branch at NICHD. He became the eleventh director of the NCI in August 1995. One of the most frequently cited scientists in the world in cellular and molecular biology, his research has been recognized with numerous awards and honors, including the Outstanding Investigator Award from the American Federation of Clinical Research and the William Damashek Prize for major discoveries in hematology. Dr. Klausner was elected to the National Academy of Sciences in 1993 and the American Academy of Arts and Sciences in 1995. He received the 1997-1998 Dickson Prize in Medicine, created to honor the nation's outstanding leaders in science and medicine, and the 1998 Raymond Bourgine Award, recognizing exceptional scientific achievements. Dr. Klausner has served on the editorial boards of several scientific journals, including Chemistry & Biology, Analytical Chemistry, New Biologist, Cell, Annual Review of Cell Biology, and the Journal of Cell Biology. He is a past president of the American Society of Clinical Investigation and has been chairman of the National Science Education Standards Projects of the National Academy of Sciences, overseeing the first comprehensive process to provide a vision of scientific literacy in the American educational system and the criteria required to achieve it. Dr. Klausner is the author of a textbook of medical immunology and of a widely used textbook of internal medicine. » back to top Raju Kucherlapati, Ph.D.
Raju Kucherlapati is a Professor of Medicine and the Paul C. Cabot Professor of Genetics at Harvard Medical School and the first Scientific Director of the Harvard-Partners Center for Genetics and Genomics. Dr. Kucherlapati came to the United States in 1967 after completing undergraduate and graduate degrees in India. He received his Ph.D. from the University of Illinois at Urbana and did his post-doctoral work in the lab of Frank Ruddle at Yale University. He was assistant professor in the Department of Biochemical Sciences at Princeton University, and then became professor in the Department of Genetics at the University of Illinois College of Medicine. In 1989 Dr. Kucherlapati went to the Albert Einstein College of Medicine where he was the Lola and Saul Kramer Professor of Molecular Genetics and Chairman of the Department of Molecular Genetics, a position he held for eleven years. Dr. Kucherlapati's research interests include cloning of human disease genes and the generation and characterization of mouse models for human disease. The Kucherlapati laboratory at Harvard Medical School has four major areas of focus: mammalian genetics, where his laboratory participated in the mapping and sequencing of the mouse and human genomes; the etiology of Velo-Cardio-Facial syndrome; generation of mouse models for human cancer; and the etiology of Noonan Syndrome. To date he holds 12 patents. He was a member of the National Advisory Council for Human Genome Research at the National Human Genomics Research Institute, and currently serves as co-chair of the steering committee for the National Cancer Institute's Mouse Models for Human Cancer Consortium. He serves on the editorial board of the New England Journal of Medicine and was editor in chief of the journal Genomics. Dr. Kucherlapati was a founder of Cell Genesys and of Millennium Pharmaceuticals. He currently serves on the boards of Millennium Pharmaceuticals and Abgenix as well as on the board of privately held AVEO Pharmaceuticals. » back to top David M. Livingston, M.D.
David Morse Livingston, M.D., is Deputy Director of the Dana-Farber/Harvard Cancer Center; Chief of The Charles A. Dana Division of Human Cancer Genetic at Dana-Farber Cancer Institute, and the Emil Frei Professor of Genetics and Medicine at Harvard Medical School. From 1996 to 2000, he served as Chairman of the Executive Committee for Research at the Dana-Farber Cancer Institute (DFCI) and he resumed that post in 2005. In this capacity, he leads the senior faculty group that oversees all aspects of the Institute's research program. From 1991 to 1995, Dr. Livingston served as Director and Physician-in-Chief at DFCI. During the period 1995 to 1999, he served as the first chair of the Board of Scientific Advisors of the National Cancer Institute and as a member of the Institute's Executive Committee. Dr. Livingston is an internationally recognized expert on genes that regulate cell growth in the body -- genes that, when they go awry, can lead to cancer. These genes are called oncogenes and tumor suppressor genes. Through his research, Dr. Livingston is working to uncover the detailed biochemical steps required to initiate and maintain the transformation of these cells into tumor cells. His focus is on the regulatory controls of signal transduction -- the smooth and coordinated flow of special chemical signals from the surrounding environment to the cell and within cells themselves where they are transduced into specific commands that tell cells whether or not to grow. Dr. Livingston received his B.A. from Harvard University (1961, cum laude), an M.D. from Tufts University School of Medicine (1965, magna cum laude), and served his internship and residency in internal medicine at the Peter Bent Brigham Hospital in Boston, now Brigham and Women's Hospital. In 1967, he became a Research Associate at the National Cancer Institute (NCI) in molecular biology and biochemistry; he continued his work as a Research Fellow in Biological Chemistry at Harvard Medical School in 1969. Dr. Livingston returned to NCI in 1971 as a Senior Staff Fellow and later became a Senior Investigator. In 1973, he joined the Harvard faculty as Assistant Professor of Medicine at DFCI and has been a faculty member continuously since. Dr. Livingston is the recipient of numerous awards and honors, including Tufts University anatomy, pathology, and top class rank prizes and Dana-Farber's Claire W. and Richard P. Morse Research Award. In 1990, he was elected to the Institute of Medicine, National Academy of Sciences. In 1995, he was elected to the National Academy of Sciences. In 2001, he was elected to the American Academy of Arts and Sciences. In 1997, he was the recipient of the Award for Distinguished Research in the Biomedical Sciences, sponsored by the Association of American Medical Colleges. Also in 1997, Dr. Livingston was a recipient of the Brinker International Award for Breast Cancer Research, presented by The Susan G. Komen Breast Cancer Foundation for Outstanding Achievements in the Field of Breast Cancer Research. In 2001, he received the Lila Gruber Cancer Research Award presented by the American Academy of Dermatology. He has also received the AACR-G.H.A. Clowes Award (2005) and the Boveri Award (2005) from the German Cancer Society. Dr. Livingston sits on the editorial boards of Molecular Cell, Genes and Development, Cell Growth & Differentiation, and Molecular and Cellular Biology. He is a member of the Association of American Physicians, the American Society for Clinical Investigation, the American Society for Microbiology, and the American Academy of Microbiology. Dr. Livingston has authored more than 190 scientific publications. » back to top Charles L. Sawyers, M.D.
Physician-scientist Charles L. Sawyers has been appointed Chairman of Memorial Sloan-Kettering Cancer Center's new Human Oncology and Pathogenesis Program (HOPP) and the first incumbent of the Marie Josée and Henry R. Kravis Chair. HOPP will capitalize on recent advances in understanding cancer cell biology and in the development of molecularly targeted drugs and other rationally based interventions. It will bring together physician-scientists from various clinical and scientific disciplines to conduct cutting-edge translational research across many types of cancer.
Dr. Sawyers comes to the Center after nearly two decades at the University of California, Los Angeles (UCLA). Dr. Sawyers’ laboratory is focused on characterizing signal transduction pathway abnormalities in various cancers, including chronic myeloid leukemia, prostate cancer and glioblastoma, with an eye toward translational implications. His research is best demonstrated through his studies of BCR-ABL tyrosine kinase function in chronic myeloid leukemia, his work with Brian Druker and Novartis in the development of the kinase inhibitor imatinib/Gleevec as primary therapy for CML, and his discovery that imatinib resistance is caused by BCR-ABL kinase domain mutations. This discovery led Dr. Sawyers to evaluate 2nd line Abl kinase inhibitors such as dasatinib (Bristol Myers Squibb) that is now approved for treatment of imatinib-resistant patients. He received his undergraduate degree from Princeton University and his medical degree from The Johns Hopkins University. He completed a residency in internal medicine at the University of California, San Francisco, Medical Center and a clinical fellowship in hematology/oncology at the UCLA School of Medicine. He was also a Howard Hughes Medical Institute Investigator at UCLA. His awards include the Doris Duke Distinguished Clinical Scientist Award, the Richard and Hinda Rosenthal Foundation Award, and the David A. Karnofsky Award. » back to top Edward M. Scolnick, M.D.
Dr. Scolnick is currently an Associate Member of the Broad Institute of MIT and Harvard and Director of the Broad's Psychiatric Diseases Initiative. From 1982 to 2003, Dr. Scolnick served in multiple capacities as President, Merck Research Laboratories and Executive Vice President for Science and Technology, Merck & Company, Inc; Executive Director and Vice President, Department of Virus and Cell Biology, and Senior Vice President, Basic Research, Merck Research Laboratories. Prior to joining Merck, Dr. Scolnick worked at the National Cancer Institute where his work demonstrated the cellular origin of sarcoma virus oncogenes in mammals and defined specific genes that cause human cancer. He also worked at the National Heart Institute where his work defined the stop signals in the genetic code and the biochemical mechanism that produces the stops. Dr. Scolnick was elected to the National Academy of Sciences in 1984 and to the American Academy of Arts and Sciences in 1993. He became a member of the Institute of Medicine in 1996 and served on the Board of Directors of Merck & Co., Inc. from 1997 to 2002. He recently was selected as Regents' Lecturer, University of California Berkeley, Frank H.T. Rhodes Class of '56 University Professor at Cornell University, and appointed to the Board of Visitors at the University of Pittsburgh School of Medicine. He currently serves on the Board of Directors for Millipore Corporation, Renovis, Inc., and TransForm Pharmaceuticals, Inc., and on the Medical and Scientific Advisory Board for MPM Capital. He was also a Member of the FDA Science Board from 2000 to 2002. Dr. Scolnick's commitment to the mental health field is evidenced by memberships on the Board of Directors for McLean Hospital and the McGovern Institute for Brain Research. Prior to moving to the Broad Institute, he was on the Board of Montgomery County Emergency Services and was President of the Montgomery County Chapter of the National Alliance for the Mentally Ill. From 1998 to 2002, he served as a member of the Council of the National Institute of Mental Health. Dr. Scolnick holds an A.B. from Harvard College and a M.D. from Harvard University Medical School.
» back to top
|
